Amiodarone: A multifaceted antiarrhythmic drug

Current Cardiology Reports

Volumn 8, Issue 5, 2006, Pages 349-355

  Singh, Bramah N ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; IBUTILIDE; IRBESARTAN; METOPROLOL; PLACEBO; PROPRANOLOL; RANOLAZINE; SEMATILIDE; SOTALOL; TRANDOLAPRIL; VERAPAMIL;

ANGINA PECTORIS; BRADYCARDIA; CLINICAL TRIAL; DEFIBRILLATION; DEIODINATION; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SYNTHESIS; HEART ARRHYTHMIA; HEART ATRIUM; HEART INFARCTION; HEART REPOLARIZATION; HEART VENTRICLE; HISTORY OF MEDICINE; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; LUNG FIBROSIS; NONHUMAN; QT PROLONGATION; REVIEW; SINUS RHYTHM; SKIN MANIFESTATION; THYROID DISEASE; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; HEART CONDUCTION SYSTEM; HUMANS;

EID: 33749011406     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0074-2     Document Type: Review

References (44)

1. Singh BN: Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996, 78:41-53.
2. Singh BN: Overview of trends in the control of cardiac arrhythmia: past and future. Am J Cardiol 1999, 84:3R-10R.
3. Singh BN: Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Antiarrhythmic Mechanisms [D.Phil thesis]. Oxford: Hertford College and University; 1971.
4. Charlier R, Deltour G, Baudine A, et al.: Pharmacology of amiodarone: an antianginal drug with a new biological profile. Arzneimittelforschung 1968, 18:1408.
5. Singh BN: A symposium: approaches to controlling cardiac arrhythmias: focus on amiodarone, the last 15 years. Am J Cardiol 1999, 84:1R-173R.
6. Singh BN, Vaughan Williams EM: The effect of amiodarone: a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970, 39:657.
7. Singh BN, Vaughan Williams EM: A third class of antiarrhythmic actions? Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970, 39:675-687.
8. Singh BN: The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol 1996, 78(Suppl 4A):17-27.
9. Connolly SJ, Dorian P, Roberts RS, et al.: Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. JAMA 2006, 295:165-171.
10. Kudenchuk PJ, Cobb LA, Copass MK, et al.: Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999, 341:871.
11. Dorian P, Cass D, Schwartz, et al.: Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002, 346:884-890.
12. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG: Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 1992, 116: 1017-1120.
13. Singh BN, Singh SN, Reda DJ, et al.: Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005, 352:1861-1872.
14. Roy D, Talajic M, Dorian P et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913-920.
15. Nattel S, Khairy P, Roy D, et al.: New approaches to atrial fibrillation management: a critical review of rapidly evolving field. Drugs 2002, 62:2377-2397.
16. Singh BN: Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Therapeut 2003, 8:13-26.
17. Deedwania PK, Singh BN, Ellenbogan K, et al.: Spontaneous conversion an maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998, 23:2574-25479.
18. Holnloser S, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Intern Med 1994, 121:529-537.
19. Hohnloser S, Singh BN: Proarrhythmia with class III antiarrhythmic drugs. Definition, electrophysiologic mechanism, incidence, predisposing factors, and clinical implications. J Electrophysiol 1995, 6:920-936.
20. Singh BN: Rise and fall of guided antiarrhythmic therapy for ventricular tachycardia and fibrillation. J Cardiovasc Pharmacol Therapeut 1996, 1:89-94.
21. Singh BN: Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996, 78:41-53.
22. Singh SN, Fletcher RD, Fisher SG, et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995, 333:77-82.
23. Singh BN: Amiodarone and homogeneity of ventricular repolarization and refractoriness. J Cardiovasc Pharmacol Therapeutics 1996, 1:265-270.
24. Amiodarone Trials Meta-Analysis Investigators: Effects of prophylactic amiodarone on mortality after myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997, 350:1417-1424.
25. Nattel S, Singh BN: Evolution, mechanisms, and classifications of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999, 84:11R-19R.
26. Connolly S: Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999, 100:2025-2034.
27. MERIT-HEFT Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
28. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Lancet 1999, 353:9-13.
29. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
30. Singh BN: Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997, 20:608-618.
31. Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
32. Singh BN: Atrial fibrillation following investigation of rhythm management: AFFIRM trial outcomes: what might be their implications for arrhythmia control? J Cardiovasc Pharmacol Ther 2002, 7:131-133.
33. Dorian P, Mangat I, Pinter A, Korley V: The burden of atrial fibrillation: Should we abandon antiarrhythmic drug therapy? J Cardiovasc Pharmacol Therapeut 2004, 9:257-262.
34. Singh BN: Editorial. Pursuit of sinus rhythm in patients with atrial fibrillation: is the effort worth it? J Cardiovasc Pharmacol Therapeut 2004, 9:219-221.
35. Boutitie F, Boissel JP, Connolly SJ, et al.: Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. Circulation 1999, 99:2268-2275.
36. Pederson OD, Bagger H, Kober L, et al.: Trandolopril reduces the incidence of atrial fibrillation after myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
37. Madrid AH, Bueno AH, Rebollo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002, 106:331-336.
38. Singh BN, Wadhani N: Antiarrhythmic and proarrhythmic properties of QT-prolonging properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Therapeut 2004, 9(Suppl 1):S85-S97.
39. Antzelevitch C, Bellardinell L, Wu Lin, et al.: Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Therapeut 2004, 9(Suppl 1z):S65-S84.
40. Sicouri S, Moro S, Litovsky S, et al.: Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 1997, 8:1269-1279.
41. Glatter K, Young Y, Chatterjee K, et al.: Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients on amiodarone therapy. Circulation 2003, 103:253-257.
42. Rochetti M, Bertrand JP, Nisato D, et al.: Cellular electrophysiological study of dronedarone, a new amiodarone-like agent, in guinea pig sino-atrial node. Arch Pharmacol 1998, 358: R617.
43. Sun W, Sarma JSM, Singh BN: Electrophsiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative in the rabbit heart. Comparison with amiodarone. Circulation 1999, 100:2276-2283.
44. Sun W, Sarma JSM, Singh BN: Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002, 39:677-684.